|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
|
Quantum Biopharma Ltd. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
74764Y205 (CUSIP Number) |
Malone Wealth Ventures 9201 W State St. Ste 126, Boise, ID, 83714 2089854526 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/12/2025 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. | 74764Y205 |
| 1 |
Name of reporting person
Malone Wealth Ventures LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
| ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
IDAHO
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
580,806.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
17.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IA |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock | |
| (b) | Name of Issuer:
Quantum Biopharma Ltd. | |
| (c) | Address of Issuer's Principal Executive Offices:
55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO,
ONTARIO, CANADA
, M5J 2H7. | |
Item 1 Comment:
Les Gro | ||
| Item 2. | Identity and Background | |
| (a) | This Schedule 13D is being filed by Kevin Malone, an individual and a U.S. citizen, and Malone Wealth Ventures LLC, a fiduciary investment advisory firm.
| |
| (b) | 9201 W State St. Ste 126,
Boise, ID, 83714 | |
| (c) | Kevin Malone is the President and CEO of Malone Wealth Ventures LLC, a fiduciary investment advisory firm located at 9201 W State St. Ste 126, Boise, ID 83714.
| |
| (d) | No | |
| (e) | No | |
| (f) | United States | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
The securities reported herein were acquired through (i) open market purchases made using client funds over which Malone Wealth Ventures LLC has discretionary investment authority, and (ii) a grant of 30,000 shares issued directly to Kevin Malone as compensation for his role as Advisor to the Board of Directors of Quantum Biopharma Inc., pursuant to a consulting agreement between Mr. Malone and the issuer. An additional 60,000 share grant was received based on continuation of work. At this time, no other grants have been discussed in the future.
| ||
| Item 4. | Purpose of Transaction | |
The securities were acquired for investment purposes. Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance. As such, the Reporting Persons may be deemed to have an intent to influence the control of the issuer.
The Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors. Except as set forth herein, the Reporting Persons do not currently have any plans or proposals which relate to or would result in any of the actions enumerated in paragraphs (a) through (j) of Item 4. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | 580,806 and 17% | |
| (b) | 52,265 | |
| (c) | The following transactions in the Common Stock of the issuer were effected by Malone Wealth Ventures LLC on behalf of advisory clients during the 60 days preceding the filing of this Schedule 13D/A. All transactions were open market purchases executed on public exchanges:
June 13, 2025 - Purchased 1,000 shares at $19.10 per share
June 13, 2025 - Purchased 10 shares at $19.25 per share
June 13, 2025 - Purchased 100 shares at $18.80 per share
June 13, 2025 - Purchased 24 shares at $19.11 per share
June 13, 2025 - Purchased 1,000 shares at $19.83 per share
June 13, 2025 - Purchased 1,000 shares at $21.10 per share
June 13, 2025 - Purchased 250 shares at $20.65 per share
June 13, 2025 - Purchased 1,000 shares at $20.65 per share
June 13, 2025 - Purchased 1,000 shares at $20.55 per share
June 13, 2025 - Purchased 1,000 shares at $20.40 per share
June 13, 2025 - Purchased 1,000 shares at $20.92 per share
June 13, 2025 - Purchased 200 shares at $20.70 per share
June 13, 2025 - Purchased 50 shares at $20.70 per share
June 13, 2025 - Purchased 25 shares at $20.70 per share
June 13, 2025 - Purchased 1,000 shares at $20.70 per share
June 13, 2025 - Purchased 40 shares at $20.70 per share
June 13, 2025 - Purchased 30 shares at $20.70 per share
June 13, 2025 - Purchased 40 shares at $20.70 per share
June 13, 2025 - Purchased 1,000 shares at $20.40 per share
June 13, 2025 - Purchased 1,000 shares at $20.30 per share
June 13, 2025 - Purchased 1,000 shares at $20.08 per share
June 13, 2025 - Purchased 1,000 shares at $19.30 per share
June 13, 2025 - Purchased 1,000 shares at $19.40 per share
June 13, 2025 - Purchased 1,000 shares at $19.30 per share
June 13, 2025 - Purchased 5,000 shares at $19.70 per share
June 16, 2025 - Purchased 1,000 shares at $21.02 per share
June 16, 2025 - Purchased 50 shares at $21.02 per share
June 16, 2025 - Purchased 100 shares at $21.02 per share
June 16, 2025 - Purchased 80 shares at $21.02 per share
June 16, 2025 - Purchased 30 shares at $21.02 per share
June 16, 2025 - Purchased 200 shares at $21.02 per share
June 16, 2025 - Purchased 200 shares at $21.02 per share
June 16, 2025 - Purchased 50 shares at $21.02 per share
June 16, 2025 - Purchased 1,000 shares at $21.57 per share
June 16, 2025 - Purchased 1,000 shares at $21.26 per share
June 16, 2025 - Purchased 100 shares at $21.58 per share
June 17, 2025 - Purchased 1,000 shares at $26.19 per share
June 17, 2025 - Purchased 1,000 shares at $24.90 per share
June 17, 2025 - Purchased 1,000 shares at $24.00 per share
June 17, 2025 - Purchased 2 shares at $25.02 per share
June 17, 2025 - Purchased 50 shares at $25.06 per share
June 17, 2025 - Purchased 400 shares at $25.06 per share
June 17, 2025 - Purchased 1,000 shares at $25.06 per share
June 17, 2025 - Purchased 12 shares at $25.02 per share
June 17, 2025 - Purchased 50 shares at $25.02 per share
June 17, 2025 - Purchased 15 shares at $25.06 per share
June 17, 2025 - Purchased 100 shares at $25.02 per share
June 17, 2025 - Purchased 11 shares at $25.00 per share
June 17, 2025 - Purchased 40 shares at $25.02 per share
June 17, 2025 - Purchased 200 shares at $25.06 per share
June 17, 2025 - Purchased 400 shares at $25.06 per share
June 17, 2025 - Purchased 190 shares at $25.06 per share
June 17, 2025 - Purchased 25 shares at $25.06 per share
June 17, 2025 - Purchased 110 shares at $25.06 per share
June 17, 2025 - Purchased 15 shares at $25.02 per share
June 17, 2025 - Purchased 20 shares at $25.02 per share
June 17, 2025 - Purchased 40 shares at $25.06 per share
June 17, 2025 - Purchased 1,000 shares at $25.50 per share
June 18, 2025 - Purchased 100 shares at $27.00 per share
June 18, 2025 - Purchased 1,000 shares at $27.95 per share
June 18, 2025 - Purchased 1,000 shares at $29.17 per share
June 18, 2025 - Purchased 1,000 shares at $30.80 per share
June 18, 2025 - Purchased 1,000 shares at $31.00 per share
June 18, 2025 - Purchased 1,000 shares at $31.31 per share
June 18, 2025 - Purchased 119 shares at $30.88 per share
June 18, 2025 - Purchased 1,000 shares at $30.24 per share
June 18, 2025 - Purchased 20 shares at $31.20 per share
June 20, 2025 - Purchased 1,000 shares at $36.71 per share
June 20, 2025 - Purchased 1,000 shares at $37.55 per share
June 20, 2025 - Purchased 1,000 shares at $37.50 per share
June 20, 2025 - Purchased 1,000 shares at $37.35 per share
June 20, 2025 - Purchased 1,000 shares at $36.26 per share
June 20, 2025 - Purchased 1,000 shares at $37.59 per share
June 20, 2025 - Purchased 1,000 shares at $35.30 per share
All trades were executed by Malone Wealth Ventures LLC and were directed all at client's requests. | |
| (d) | The clients of Malone Wealth Ventures LLC, as beneficial owners of the securities managed on a discretionary basis, have the right to receive dividends and the proceeds from the sale of such securities. None of the individual clients, to the best knowledge of the Reporting Persons, holds more than 5% of the issuer's outstanding shares. | |
| (e) | Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Pursuant to an agreement with the issuer, Quantum Biopharma Inc., Kevin Malone serves as an advisor to the Board of Directors. In connection with this engagement, the Reporting Person received a grant of 30,000 restricted stock units (RSUs), with additional RSUs issuable upon the achievement of certain goals.
The Reporting Person disclaims beneficial ownership of the unvested RSUs except to the extent that such rights are vested or become exercisable within 60 days of the date of this filing.
Other than as described herein, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Persons and any other person with respect to any securities of the issuer.
| ||
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 1 Advisory and Equity Compensation Agreement between Kevin Malone and Quantum Biopharma Inc., dated April 15th, 2025.
| ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|